Regenicin (RGIN) 10-Q 14 Aug 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Jun. 30, 2015	Jul. 15, 2015
Document And Entity Information
Entity Registrant Name	Regenicin, Inc.
Entity Central Index Key	1,412,659
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		153,483,050
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,015

CONSOLIDATED BALANCE SHEET

CONSOLIDATED BALANCE SHEET - USD ($)	Jun. 30, 2015	Sep. 30, 2014
CURRENT ASSETS
Cash	$ 1,431,251	$ 492
Prepaid expenses and other current assets	86,208	$ 49,462
Common stock of Amarantus Corporation	$ 1,562,500
Deferred income taxes		$ 2,829,000
Total current assets	$ 3,079,959	2,878,954
Intangible assets		7,500
Total assets	$ 3,079,959	2,886,454
CURRENT LIABILITIES
Accounts payable	379,420	1,393,605
Accrued expenses	1,295,556	1,740,090
Dividends payable	$ 304,197	251,242
Note payable - insurance financing		51,613
Bridge financing	$ 175,000	450,000
Convertible promissory notes (net of discount of $-0- and $20,645)		295,617
Loan payable	$ 10,000	10,000
Loans payable - related parties	$ 95,000	205,817
Derivative liabilities		5,164
Total current and total liabilities	$ 2,259,173	4,403,148
STOCKHOLDERS EQUITY (DEFICIENCY)
Series A 10% Convertible Preferred stock, $0.001 par value, 5,500,000 shares authorized;885,000 issued and outstanding	885	885
Common stock, $0.001 par value; 200,000,000 shares authorized; 157,911,410 and 139,598,152 issued, respectively; 153,483,050 and 135,169,792 outstanding, respectively	$ 157,914	139,601
Common stock to be issued; 0 and 10,367,094 shares		402,040
Additional paid-in capital	$ 9,805,423	8,897,799
Accumulated deficit	(7,701,508)	$ (10,952,591)
Accumulated other comprehensive loss	(1,437,500)
Less: treasury stock; 4,428,360 shares at par	(4,428)	$ (4,428)
Total stockholders equity (deficiency)	820,786	(1,516,694)
Total liabilities and stockholders equity (deficiency)	$ 3,079,959	$ 2,886,454

CONSOLIDATED BALANCE SHEET (Par

CONSOLIDATED BALANCE SHEET (Parenthetical) - USD ($)	Jun. 30, 2015	Sep. 30, 2014
Statement of Financial Position [Abstract]
Series A Preferred Stock, Par Value	$ 0.001	$ 0.001
Series A Preferred Stock, Shares Authorized	5,500,000	5,500,000
Series A Preferred Stock, Issued and outstanding	885,000	885,000
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Issued	157,911,410	139,598,152
Common Stock, Outstanding	153,483,050	135,169,792
Common Stock, To Be Issued	0	10,367,094
Treasury Stock, Issued	4,428,360	4,428,360
Convertible promissory note discount	$ 0	$ 20,645

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Revenues
Operating expenses
Research and development			$ 33,400
General and administrative	$ 438,502	$ 88,547	845,319	$ 548,491
Stock based compensation - general and administrative			32,365	$ 27,556
Reversal of accounts payable - Lonza			(973,374)
Total operating expenses	$ 438,502	$ 88,547	(62,290)	$ 576,047
Income (loss) from operations	(438,502)	(88,547)	62,290	(576,047)
Other income (expenses)
Interest expense, including amortization of debt discounts and beneficial conversion features	$ (18,407)	$ (76,554)	(58,408)	$ (206,535)
Gain on sale of assets			6,604,431
Gain (loss) on derivative liabilities		$ (143,763)	(528,230)	$ 82,961
Total other income (expenses)	$ (18,407)	(220,317)	6,017,793	(123,574)
Income (loss) before income taxes	$ (456,909)	$ (308,864)	6,080,083	$ (699,621)
Income tax expense			2,829,000
Net income (loss)	$ (456,909)	$ (308,864)	3,251,083	$ (699,621)
Preferred stock dividends	(17,652)	(17,652)	(52,955)	(52,955)
Net income (loss) attributable to common stockholders	$ (474,561)	$ (326,516)	$ 3,198,128	$ (752,576)
Income (loss) per share Basic	$ 0	$ 0	$ 0.02	$ (0.01)
Income (loss) per share Diluted	$ 0	$ 0	$ 0.02	$ (0.01)
Weighted average number of shares outstanding Basic	153,483,049	136,432,523	153,188,645	130,739,786
Weighted average number of shares outstanding Diluted	153,483,049	136,432,523	162,038,645	130,739,786

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Consolidated Statements Of Comprehensive Income Loss
Net income (loss)	$ (456,909)	$ (308,864)	$ 3,251,083	$ (699,621)
Other comprehensive income:
Change in unrealized loss on available-for-sale securities, net of income taxes	62,500		(1,437,500)
Comprehensive income (loss)	$ (394,409)	$ (308,864)	$ 1,813,583	$ (699,621)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)	$ 3,251,083	$ (699,621)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Deferred income taxes	2,829,000
Amortization of debt discounts	7,675	$ 148,667
Accrued interest on notes and loans payable	$ (7,114)	59,289
Amortization of beneficial conversion features		54,545
Original interest discount on convertible note payable		4,156
Stock based compensation - G&A	$ 32,365	27,556
(Gain) loss on derivative liabilities	528,230	$ (82,961)
Gain on sale of assets	(6,604,431)
Reversal of accounts payable	$ (973,374)
Other gain related to derivative liabilities		$ (63,095)
Expenses paid directly by officer	$ 95,000
Changes in operating assets and liabilities
Prepaid expenses and other current assets	(36,746)	$ 54,274
Accounts payable	(361,059)	5,516
Accrued expenses	(387,440)	323,172
Net cash used in operating activities	(1,626,811)	$ (168,502)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sale of assets
Purchase of intangible assets	(10,000)
Net cash provided by investing activities	$ 3,590,000
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from the issuance of notes payable		$ 100,000
Repayments of notes payable	$ (275,000)
Proceeds from loans from related parties	23,330	$ 98,442
Repayments of loans from related party	(229,147)	(500)
Repayments of notes payable - insurance financing	$ (51,613)	(52,220)
Proceeds from the sale of common stock		640
Net cash (used in) provided by financing activities	$ (532,430)	146,362
NET INCREASE (DECREASE) IN CASH	1,430,759	(22,140)
CASH - BEGINNING OF PERIOD	492	22,500
CASH - END OF PERIOD	1,431,251	360
Supplemental disclosures of cash flow information:
Cash paid for interest	$ 13,447	$ 3,894
Cash paid for income taxes
Non-cash activities:
Sale of assets	$ 6,600,000
Common Stock of Amarantus received	(3,000,000)
Cash received	3,600,000
Preferred stock dividends	52,955	$ 52,955
Shares issued/to be issued in connection with conversion of debt and accrued interest	$ 11,091	313,720
Beneficial conversion feature and warrant value on bridge financing		75,000
Derivative liabilities reclassified to additional paid-in capital	$ 533,394	84,070
Common stock issued for accrued expenses		$ 35,851

THE COMPANY

THE COMPANY	9 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
THE COMPANY	The Company’s business plan is to develop and commercialize a potentially lifesaving technology by the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of plastic surgery procedures. The Company entered into a Know-How License and Stock Purchase Agreement (the “Know-How SPA”) with Lonza Walkersville, Inc. (“Lonza Walkersville”) on July 21, 2010. Pursuant to the terms of the Know-How SPA, the Company paid Lonza Walkersville $3,000,000 and, in exchange, the Company was to receive an exclusive license to use certain proprietary know-how and information necessary to develop and seek approval by the U.S. Food and Drug Administration (“FDA”) for the commercial sale of technology held by the Cutanogen Corporation (“Cutanogen”), a subsidiary of Lonza Walkersville. Additionally, pursuant to the terms of the Know-How SPA, the Company was entitled to receive certain related assistance and support from Lonza Walkersville upon payment of the $3,000,000. Under the Know-How SPA, once FDA approval was secured for the commercial sale of the technology, the Company would be entitled to acquire Cutanogen, Lonza Walkersville’s subsidiary, for $2,000,000 in cash. After prolonged attempts to negotiate disputes with Lonza Walkersville failed, on September 30, 2013, the Company filed a lawsuit against Lonza Walkersville, Lonza Group Ltd. and Lonza America, Inc. (“Lonza America”) in Fulton County Superior Court in the State of Georgia. On November 7, 2014, the Company entered into an Asset Sale Agreement (the “Sale Agreement”) with Amarantus Bioscience Holdings, Inc., (“Amarantus”). Under the Sale Agreement, the Company agreed to sell to Amarantus all of its rights and claims in the litigation currently pending in the United States District Court for the District of New Jersey against Lonza Walkersville and Lonza America, Inc. (the “Lonza Litigation”). This includes all of the Cutanogen intellectual property rights and any Lonza manufacturing know-how technology. In addition, the Company agreed to sell the PermaDerm® trademark and related intellectual property rights associated with it. The purchase price paid by Amarantus was: (i) $3,600,000 in cash, and (ii) shares of common stock in Amarantus having a value of $3,000,000. See Note 4 for a further discussion. The Company intends to use the net proceeds of the transaction to fund development of cultured cell technology and to pursue approval of the products through the U.S. Food and Drug Administration. We have been developing our own unique cultured skin substitute since we received Lonza’s termination notice.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	Interim Financial Statements: The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the year ending September 30, 2015. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended September 30, 2014, as filed with the Securities and Exchange Commission. Going Concern: The Company's consolidated financial statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Although the Company has received cash flows from the Sale Agreement, it does not have a source of revenue and is incurring routine expenses. The Company expects to incur further losses in the development of its business and has been dependent on funding operations through the issuance of convertible debt and private sale of equity securities. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans include continuing to finance operations through the private or public placement of debt and/or equity securities. However, no assurance can be given at this time as to whether the Company will be able to achieve these objectives. The consolidated financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Financial Instruments and Fair Value Measurement: The Company measures fair value of its financial assets on a three-tier value hierarchy, which prioritizes the inputs, used in the valuation methodologies in measuring fair value: • Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. • Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable or inputs that can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 - Unobservable inputs which are supported by little or no market activity. The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The carrying value of cash, prepaid expenses and other current assets, accounts payable, accrued expenses and all loans and notes payable in the Company’s consolidated balance sheets approximated their values as of June 30, 2015 and September 30, 2014 due to their short-term nature. Common stock of Amarantus represents equity investments in common stock that the Company classifies as available for sale. Such investments are carried at fair value in the accompanying consolidated balance sheets. Fair value is determined under the guidelines of GAAP which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. Realized gains and losses, determined using the first-in, first-out (FIFO) method, are included in net income. Unrealized gains and losses are reported as other comprehensive income and are included in equity. The common stock of Amarantus is valued at the closing price reported on the active market on which the security is traded. This valuation methodology is considered to be using Level 1 inputs. The total value of Amarantus common stock at June 30, 2015 is $1,562,500. The unrealized loss for the nine months ended June 30, 2015 was $1,437,500 net of income taxes, and was reported as a component of comprehensive income. The Company issued notes payable that contained conversion features which were accounted for separately as derivative liabilities and measured at fair value on a recurring basis. Changes in fair value are charged to other income (expenses) as appropriate. The fair value of the derivative liabilities was determined based on Level 2 inputs utilizing observable quoted prices for similar instruments in active markets and observable quoted prices for identical or similar instruments in markets that are not very active. Derivative liabilities totaled $-0- and $5,164 as of June 30, 2015 and September 30, 2014, respectively. See Note 7 - Notes Payable - Convertible Promissory Notes for additional information. Recent Pronouncements: Management does not believe that any of the recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying consolidated financial statements.

INCOME (LOSS) PER SHARE

INCOME (LOSS) PER SHARE	9 Months Ended
	Jun. 30, 2015
Notes to Financial Statements
INCOME (LOSS) PER SHARE	Basic income (loss) per share is computed by dividing the net income (loss) by the weighted average number of common shares outstanding during the period. Diluted loss per share gives effect to dilutive convertible securities, options, warrants and other potential common stock outstanding during the period; only in periods in which such effect is dilutive. The following table summarizes the components of the income (loss) per common share calculation: Nine Months Ended Three Months Ended June 30, June 30, 2015 2014 2015 2014 Income (Loss) Per Common Share - Basic: Net income (loss) available to common stockholders $ 3,198,128 $ (752,576 ) $ (474,561 ) $ (326,516 ) Weighted-average common shares outstanding 153,188,645 130,739,786 153,483,049 136,432,523 Basic income (loss) per share $ 0.02 $ (0.01 ) $ (0.00 ) $ (0.00 ) Income (Loss) Per Common Share - Diluted: Net income (loss) available to common shareholders $ 3,198,128 $ (752,576 ) $ (474,561 ) $ (326,516 ) Dividends on convertible preferred stock 52,955 — — — Adjusted net income (loss) available to common shareholders $ 3,251,083 $ (752,576 ) $ (474,561 ) $ (326,516 ) Weighted-average common shares outstanding 153,188,645 130,739,786 153,483,049 136,432,523 Convertible preferred stock 8,850,000 — — — Weighted-average common shares outstanding and common share equivalents 162,038,645 130,739,786 153,483,049 136,432,523 Diluted income (loss) per share $ 0.02 $ (0.01 ) $ (0.00 ) $ (0.00 ) The following securities have been excluded from the diluted per share calculation for the nine ended June 30, 2015 because the exercise price was greater than the average market price of the common shares: Options 15,542,688 Warrants 3,061,667 The following securities have been excluded from the calculation of net loss per share for the three months ended June 30, 2015 and the nine and three months ended June 30, 2014, as their effect would be anti-dilutive: Three Months Ended Three and Nine Months June 30, 2014 Options 15,542,688 5,542,688 Warrants 3,061,667 3,611,167 Convertible preferred stock 885,000 17,700,000 Convertible debentures — 26,198,825

SALE OF ASSET

SALE OF ASSET	9 Months Ended
	Jun. 30, 2015
Notes to Financial Statements
SALE OF ASSET	On November 7, 2014, the Company entered into a Sale Agreement with Amarantus, Clark Corporate Law Group LLP ("CCLG") and Gordon & Rees, LLP (“Gordon & Rees”). Under the Sale Agreement, the Company agreed to sell to Amarantus all of its rights and claims in the Lonza Litigation. These include all of the Cutanogen intellectual property rights and any Lonza manufacturing know-how technology. In addition, the Company has agreed to sell its PermaDerm® trademark and related intellectual property rights associated with it. The purchase price to be paid by Amarantus was of: (i) $3,500,000 in cash, and (ii) shares of common stock in Amarantus having a value of $3,000,000. A portion of the cash purchase price is allocated to repay debt. On January 30, 2015, the agreement was amended whereby the cash portion of the purchase price was increased by $100,000 to $3,600,000 and the final payment was extended to February 20, 2015. The final payment of $2,500,000 was made on February 24, 2015. The payments to CCLG, satisfied in full the obligations owed to CCLG under its secured promissory note. The $3,000,000 in Amarantus common stock was satisfied by the issuance of 37,500,000 shares of Amarantus common stock from Amarantus to the Company. In addition to the sale price, Amarantus paid Gordon & Rees $450,000 at closing. The payment to Gordon & Rees was to satisfy in full all contingent litigation fees and costs owed to Gordon & Rees in connection with the Lonza Litigation. During the nine months ended June 30, 2015, the Company recorded a gain on sale of assets in the amount of $6,604,431. In addition, as a result of the Sale Agreement, the Company determined that it is no longer liable for accounts payable to Lonza in the amount of $973,374. The liability has been reversed and is included in operating expenses as an item of income. The Company also granted to Amarantus an exclusive five (5) year option to license any engineered skin designed for the treatment of patients designated as severely burned by the FDA developed by the Company. Amarantus can exercise this option at a cost of $10,000,000 plus a royalty of 5% on gross revenues in excess of $150 million.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	9 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLES ASSETS	As discussed in Note 1, the Company paid $3,000.000 to Lonza in 2010 to purchase an exclusive know-how license and assistance in gaining FDA approval. The $3,000,000 payment was recorded as an intangible asset. Due to ongoing disputes and pending any settlement of the lawsuit, the Company subsequently determined that the value of the intangible asset and related intellectual property had been fully impaired. As a result, the Company wrote down the value of the intangible asset to $0 during the year ended September 30, 2013. The Company paid $7,500 in August 2010 and $10,000 in November 2014 to obtain the rights to the trademark PermaDerm® from KJR-10 Corp. As discussed in Note 4, the Company sold all its intangible assets on November 7, 2014. At September 30, 2014, intangible assets totaled $7,500.

LOANS PAYABLE - RELATED PARTIES

LOANS PAYABLE - RELATED PARTIES	9 Months Ended
	Jun. 30, 2015
Notes to Financial Statements
LOANS PAYABLE	Loan Payable: In February 2011, an investor advanced $10,000. The loan does not bear interest and is due on demand. At both March 31, 2015 and September 30, 2014, the loan payable totaled $10,000. Loans Payable - Related Parties: In October 2011, Craig Eagle, a director of the Company, made advances to the Company. The loan bears interest at 5% and is due on demand. At September 30, 2014, the loan balance was $38,221 and was repaid in April 2015. John Weber, the Company’s Chief Financial Officer, has made advances to the Company. The loan bears interest at 5% and is due on demand. At September 30, 2014, the loan balance was $122,100 and was repaid in April 2015. Randall McCoy, the Company’s Chief Executive Officer, has made advances to the Company. The loan bears interest at 5% and is due on demand. During the quarter ended June 30, 2015, $95,000 of Company expenses paid directly by McCoy were submitted for reimbursement. These expenses had not been reimbursed to McCoy by a former underwriter. At June 30, 2015 and September 30, 2014, the loan balance was $95,000 and $8,500. In March through September 2014, the Company received other advances from related parties totaling $35,696. The loan bears interest at 5% and is due on demand. At September 30, 2014 the loan balances were $36,996 and were repaid in April 2015. At June 30, 2015 and September 30, 2014, loans payable - related parties totaled $95,000 and $205,817, respectively.

NOTES PAYABLE

NOTES PAYABLE	9 Months Ended
	Jun. 30, 2015
Notes to Financial Statements
NOTES PAYABLE	Insurance Financing Note: In September 2014, the Company financed certain insurance premiums totaling $51,613. The note requires an initial down payment of $10,322 and is payable over a nine-month term with interest at 6.45%. At September 30, 2014, the balance owed under the note was $51,613 and was paid in full in June 2015. Bridge Financing: On December 21, 2011, the Company issued a $150,000 promissory note (“Note 2”) to an individual. Note 2 bears interest so that the Company would repay $175,000 on the maturity date of June 21, 2012, which correlated to an effective rate of 31.23%. Additional interest of 10% will be charged on any late payments. Note 2 was not paid at the maturity date and the Company is incurring additional interest described above. At both June 30, 2015 and September 30, 2014, the Note 2 balance was $175,000. In May 2013, the Company issued a convertible promissory note (“Note 29”) totaling $25,000 to an individual. Note 29 bore interest at the rate of 8% per annum and was due in November 2013. Note 29 and accrued interest thereon were convertible into shares of common stock at the rate of $0.05 per share and automatically converted on the maturity date unless paid sooner by the Company. The Company did not record a discount for the conversion feature as the conversion price was greater than the price of the common stock on the issuance date. At maturity, the principal and interest were scheduled to convert to 520,055 shares of common stock but the individual waived the conversion of the principal and accrued interest. At September 30, 2014 the Note 29 balance was $25,000. In February 2015 the loan was repaid full. In August 2013, the Company issued convertible promissory notes (“Note 35-36”) totaling $250,000 to two individuals. The notes bore interest at the rate of 8% per annum and were due in August 2014. The principal and accrued interest thereon were convertible into shares of common stock at the rate of $0.03 per share and automatically convert on the maturity dates unless paid sooner by the Company. The Company did not record discounts for the conversion features as the conversion prices were greater than the prices of the common stock on the issuance dates. At maturity, the principal and interest were scheduled to automatically convert into 4,500,000 shares of common stock but the individuals waived the conversion of the principal and accrued interest. At September 30, 2014, the balance of Notes 35-36 was $250,000. In November 2014 the Company repaid $25,000 of principal on each note and in February 2015 the remaining $225,000 of principal was repaid. Convertible Promissory Note: In October 2012, the Company issued a promissory note to a financial institution (the “Lender”) to borrow up to a maximum of $225,000. The note bears interest so that the Company would repay a maximum of $250,000 at maturity, which correlated to an effective rate of 10.59%. From inception until February 2014, the Company received $175,000. Material terms of the note include the following: 1. The Lender may make additional loans in such amounts and at such dates at its sole discretion. 2. The maturity date of each loan is one year after such loan is received. 3. The original interest discount is prorated to each loan received. 4. Principal and accrued interest is convertible into shares of the Company’s common stock at the lesser of $0.069 or 65%-70% (as defined) of the lowest trading price in the 25 trading days previous to the conversion. 5. Unless otherwise agreed to in writing by both parties, at no time can the Lender convert any amount of the principal and/or accrued interest owed into common stock that would result in the Lender owning more than 4.99% of the common stock outstanding. 6. There is a one-time interest payment of 10% of amounts borrowed that is due at the maturity date of each loan. 7. At all times during which the note is convertible, the Company shall reserve from its authorized and unissued common stock to provide for the issuance of common stock under the full conversion of the promissory note. The Company will at all times reserve at least 13,000,000 shares of its common stock for conversion. 8. The Company agreed to include on its next registration statement it files, all shares issuable upon conversion of balances due under the promissory note. Failure to do so would result in liquidating damages of 25% of the outstanding principal balance of the promissory note but not less than $25,000. In October 2014, the remaining balance due on these notes of $9,592 plus accrued interest of $1,499 was converted into 7,920,291 shares of the Company’s common stock. The conversion feature contained in the promissory note is considered to be an embedded derivative. The Company bifurcated the conversion feature and recorded a derivative liability on the consolidated balance sheet. The Company recorded the derivative liability equal to its estimated fair value. Such amount was also recorded as a discount to the convertible promissory note and is being amortized to interest expense using the effective interest method. For the nine and three months ended June 30, 2015, amortization of the debt discount amounted to $7,675 and $0, respectively. For the nine and three months ended June 30, 2014, amortization of the debt discount amounted to $57,766 and $23,017, respectively. At June 30, 2015 and September 30, 2014, the unamortized discount was $0 and $7,675, respectively. The Company is required to mark-to-market the derivative liability at the end of each reporting period. For the nine and three months ended June 30, 2015, the Company recorded a gain on the change in fair value of the conversion option of $5,163 and $-0-, respectively. For the nine and three months ended June 30, 2014, the Company recorded a gain on the change in fair value of the conversion option of $75,174 and $248,240, respectively. As of June 30, 2015 and September 30, 2014 the fair value of the conversion option was $0 and $5,163, respectively. In May 2013, the Company issued a convertible promissory note totaling $293,700 to CCLG in lieu of amounts payable. The note bears interest at the rate of 12% per annum and was originally due November 21, 2013. The maturity date of the note was extended to August 31, 2014. The note is secured by all of the assets of the Company. The note and accrued interest are convertible into shares of common stock at a conversion rate of the lower of $0.04 per share or 80% of the average of the lowest three trading prices in the 20 trading days previous to the conversion but the number of shares that can be issued is limited as defined in the note agreement. In addition, the Company issued a five-year warrant to purchase an additional 50,000 shares of common stock at a per share exercise price of the lower of $0.04 per share or 80% of the average of the lowest three trading prices in the 20 trading days previous to the conversion. The note was not paid at the maturity date but no action was taken by CCLG. During the period from October 1, 2014 through February 25, 2015, the Company repaid the total amount outstanding. The conversion features contained in the promissory note and the warrant were considered to be embedded derivatives. The Company bifurcated the conversion features and recorded derivative liabilities on the consolidated balance sheet. The Company recorded the derivative liabilities equal to their estimated fair value. Such amount was also recorded as a discount to the convertible promissory note and was amortized to interest expense using the effective interest method. For the nine months ended June 30, 2014, amortization of the debt discount amounted to $64,104. The debt discount was fully amortized as of September 30, 2014. The Company is required to mark-to-market the derivative liabilities at the end of each reporting period. For the nine and three months ended June 30, 2015, the Company recorded a gain (loss) on the change in fair value of the conversion option of $(533,393) and $-0-, respectively. For the nine and three months ended June 30, 2014, the Company recorded a gain (loss) on the change in fair value of the conversion option of $28,661 and $(122,889), respectively. As of both June 30, 2015 and September 30, 2014, the fair value of the conversion option was $-0-. At June 30, 2015 and September 30, 2014, the balance of the convertible note was $-0- and $295,617, respectively.

INCOME TAXES

INCOME TAXES	9 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES	The Company did not incur current tax expense for the nine months ended June 30, 2015 and 2014. The provision for income taxes of $2,829,000 for the nine months ended June 30, 2015 represents deferred taxes. There was no provision for the nine months ended June 30, 2014. At June 30, 2015, the Company had available approximately $3.5 million of net operating loss carry forwards which expire in the years 2028 through 2033. Significant components of the Company’s deferred tax assets at June 30, 2015 and September 30, 2014 are as follows: June 30, 2015 September 30, 2014 Net operating loss carry forwards $ 1,412,233 $ 2,850,535 Intangible assets — 1,200,000 Stock based compensation 355,265 355,265 Accrued expenses 446,781 539,912 Total deferred tax assets 2,214,279 4,945,712 Valuation allowance (2,214,279 ) (2,116,712 ) Net deferred tax assets $ — $ 2,829,000 Due to the uncertainty of their realization, a valuation allowance has been established for all of the income tax benefit for these deferred tax assets as of June 30, 2015. At both June 30, 2015 and September 30, 2014, the Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were required. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company recognizes interest and penalties related to uncertain tax positions in general and administrative expense. During the nine months ended June 30, 2015 and 2014, the Company has not recorded any provisions for accrued interest and penalties related to uncertain tax positions. The Company files its federal income tax returns under a statute of limitations. The 2011 through 2014 tax years generally remain subject to examination by federal tax authorities. The Company has not filed any of its state income tax returns since inception. Due to recurring losses, management believes that once such returns are filed, the Company would incur state minimum tax liabilities that were not deemed material to accrue.

STOCKHOLDERS DEFICIENCY

STOCKHOLDERS DEFICIENCY	9 Months Ended
	Jun. 30, 2015
Equity [Abstract]
STOCKHOLDERS (DEFICIENCY) EQUITY	Preferred Stock: Series A Series A Preferred pays a dividend of 8% per annum on the stated value and have a liquidation preference equal to the stated value of the shares. Each share of Preferred Stock has an initial stated value of $1 and was convertible into shares of the Company’s common stock at the rate of 10 for 1. The dividends are cumulative commencing on the issue date whether or not declared. Dividends amounted to $52,955 for both the nine months and $17,652 for both the three months ended June 30, 2015, and 2014. At June 30, 2015 and September 30, 2014, dividends payable total $304,197 and $251,242, respectively, and are included in accrued expenses. At both June 30, 2015 and September 30, 2014, 885,000 shares of Series A Preferred were outstanding. Series B On January 23, 2012, the Company designated a new class of preferred stock called Series B Convertible Preferred Stock (“Series B Preferred”). Four million shares have been authorized with a liquidation preference of $2.00 per share. Each share of Series B Preferred is convertible into ten shares of common stock. Holders of Series B Convertible Preferred Stock have a right to a dividend (pro-rata to each holder) based on a percentage of the gross revenue earned by the Company in the United States, if any, and the number of outstanding shares of Series B Convertible Preferred Stock, as follows: Year 1 - Total Dividend to all Series B holders = .03 x Gross Revenue in the U.S. Year 2 - Total Dividend to all Series B holders = .02 x Gross Revenue in the U.S. Year 3 - Total Dividend to all Series B holders = .01 x Gross Revenue in the U.S. At March 31, 2015, no shares of Series B Preferred are outstanding. Common Stock Issuances: In October 2014, the Company issued 7,920,291 shares of its common stock for the conversion of principal and accreted interest owed to the Lender. $7,920 was credited to common stock and $3,171 to additional paid in capital. On March 31, 2015, the Company issued 9,486,430 shares of its common stock that had previously been classified as common stock to be issued upon conversion of principal and accrued interest owed to a lender. $9,512 was credited to common stock and $348,586 was credited to additional paid in capital. In June 2015, the Company issued 880,664 shares of its common stock that had previously been classified as common stock to be issued upon conversion of principal and accrued interest owed to lenders. $881 was credited to common stock and $43,061 was credited to additional paid in capital. Stock-Based Compensation: The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with FASB ASC 505, “ Equity On January 6, 2011, the Company approved the issuance of 885,672 options to each of the four members of the board of directors at an exercise price of $0.62 per share that expire on December 22, 2015. On December 10, 2013, the exercise price of the options was changed to $0.035 per share. As a result, the Company revalued the options as required under generally accepted accounting principles and recognized an expense of $27,556. The options were revalued utilizing the Black-Scholes option pricing model with the following assumptions: exercise price: $0.035 - $0.62; expected volatility: 20.71%; risk-free rate: 0.13% - 0.14%; expected term: 1 year. On January 15, 2015, the Company entered into a stock option agreement with an officer of the Company. The agreement grants the Officer an option to purchase 10 million shares of common stock at $0.02 per share. The agreement expires on January 15, 2019. The options were valued utilizing the Black-Scholes option pricing model with the following assumptions: exercise price: $0.02; expected volatility: 22.16%; risk-free rate: .75%; expected term: 3 years. The grant date fair value was $0.02 and the options vest immediately. The expected life is the number of years that the Company estimates, based upon history, that warrants will be outstanding prior to exercise or forfeiture. Expected life is determined using the “simplified method” permitted by Staff Accounting Bulletin No. 107. The stock volatility factor is based on the Nasdaq Biotechnology Index. The Company did not use the volatility rate for Company’s common stock as the Company’s common stock had not been trading for the sufficient length of time to accurately compute its volatility when these options were issued. Stock based compensation amounted to $32,365 and $0 for the nine and three months ended June 30, 2015, respectively and $27,556 and $0 for the nine and three months ended June 30, 2014, respectively. Stock based compensation is included in general and administrative expenses.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	The Company’s principal executive offices are located in Little Falls, New Jersey. The headquarters is located in the offices of McCoy Enterprises LLC, an entity controlled by Mr. McCoy. The Company also maintains an office in Pennington, New Jersey, which is the materials and testing laboratory. An employee of the Company is an owner of Materials Testing Laboratory. No rent is charged for either premise.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	Management has evaluated subsequent events through the date of this filing.

INCOME (LOSS) PER SHARE (Tables

INCOME (LOSS) PER SHARE (Tables)	9 Months Ended
	Jun. 30, 2015
Income Loss Per Share Tables
Schedule of Income Loss per Common Share	Nine Months Ended Three Months Ended June 30, June 30, 2015 2014 2015 2014 Income (Loss) Per Common Share - Basic: Net income (loss) available to common stockholders $ 3,198,128 $ (752,576 ) $ (474,561 ) $ (326,516 ) Weighted-average common shares outstanding 153,188,645 130,739,786 153,483,049 136,432,523 Basic income (loss) per share $ 0.02 $ (0.01 ) $ (0.00 ) $ (0.00 ) Income (Loss) Per Common Share - Diluted: Net income (loss) available to common shareholders $ 3,198,128 $ (752,576 ) $ (474,561 ) $ (326,516 ) Dividends on convertible preferred stock 52,955 — — — Adjusted net income (loss) available to common shareholders $ 3,251,083 $ (752,576 ) $ (474,561 ) $ (326,516 ) Weighted-average common shares outstanding 153,188,645 130,739,786 153,483,049 136,432,523 Convertible preferred stock 8,850,000 — — — Weighted-average common shares outstanding and common share equivalents 162,038,645 130,739,786 153,483,049 136,432,523 Diluted income (loss) per share $ 0.02 $ (0.01 ) $ (0.00 ) $ (0.00 )
Schedule Of Income Loss per Common Share Exclusions	Three Months Ended Three and Nine Months June 30, 2014 Options 15,542,688 5,542,688 Warrants 3,061,667 3,611,167 Convertible preferred stock 885,000 17,700,000 Convertible debentures — 26,198,825

INCOME TAXES (Tables)

INCOME TAXES (Tables)	9 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Deferred Tax Assets	June 30, 2015 September 30, 2014 Net operating loss carry forwards $ 1,412,233 $ 2,850,535 Intangible assets — 1,200,000 Stock based compensation 355,265 355,265 Accrued expenses 446,781 539,912 Total deferred tax assets 2,214,279 4,945,712 Valuation allowance (2,214,279 ) (2,116,712 ) Net deferred tax assets $ — $ 2,829,000

THE COMPANY (Details Narrative)

THE COMPANY (Details Narrative) - USD ($)	9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Payment to Acquire Intangible Assets	$ (10,000)
Purchase Price
Sale Agmt
Date of Agreement	Nov. 7, 2014
Purchase Price	$ 3,500,000
Know How SPA
Date of Agreement	Jul. 21, 2010
Payment to Acquire Intangible Assets	$ 3,000,000
Payment to Acquire Subsidiary	$ 2,000,000

BASIS OF PRESENTATION (Details

BASIS OF PRESENTATION (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Common stock of Amarantus Corporation	$ 1,562,500		$ 1,562,500
Change in unrealized gains on available-for-sale securities, net of	$ 62,500		$ (1,437,500)
Derivative liabilities					$ 5,164

Schedule of Income Loss per Com

Schedule of Income Loss per Common Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income (Loss) Per Common Share Basic
Net income (loss) attributable to common stockholders	$ (474,561)	$ (326,516)	$ 3,198,128	$ (752,576)
Weighted average number of shares outstanding Basic	153,483,049	136,432,523	153,188,645	130,739,786
Basic income (loss) per share	$ 0	$ 0	$ 0.02	$ (0.01)
Income (Loss) Per Common Share Diluted
Net income (loss) attributable to common shareholders	$ (474,561)	$ (326,516)	$ 3,198,128	$ (752,576)
Dividends on convertible preferred stock			52,955
Adjusted net income (loss) available to common shareholders	$ (474,561)	$ (326,516)	$ 3,251,083	$ (752,576)
Weighted average number of shares outstanding Basic	153,483,049	136,432,523	153,188,645	130,739,786
Convertible preferred stock	$ 8,850,000		$ 8,850,000
Weighted average number of shares outstanding Diluted	153,483,049	136,432,523	162,038,645	130,739,786
Income (loss) per share Diluted	$ 0	$ 0	$ 0.02	$ (0.01)

LOSS PER SHARE - Schedule Of In

LOSS PER SHARE - Schedule Of Income Loss per Common Share Exclusions (Details)	Jun. 30, 2015shares
Exclusions - Calcs
Options	5,542,688
Warrants	3,061,667
Convertible preferred stock	17,700,000
Convertible debentures	30,022,775
Exclusions - Diluted Calcs
Options	15,542,688
Warrants	3,061,667
Convertible preferred stock	17,000,000
Convertible debentures	26,198,925

SALE OF ASSET (Details Narrativ

SALE OF ASSET (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended	9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2015	Jun. 30, 2014
Common Stock of Amarantus received				$ (3,000,000)
Purchase Price
Gain on sale of assets				$ 6,604,431
Sale Agmt
Date of Agreement				Nov. 7, 2014
Common Stock of Amarantus received				$ 3,000,000
Purchase Price				$ 3,500,000
Common Stock of Amarantus received, shares				37,500,000
Sale Agmt Amendment
Date of Agreement			Jan. 30, 2015
Purchase Price			$ 3,600,000
Exclusive License Grant
Purchase Price				$ 10,000,000
Option, Term				P5Y
Royalty Fee				5.00%

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Sep. 30, 2010	Sep. 30, 2014
Payment to Acquire Intangible Assets	$ (10,000)
Intangible assets				$ 7,500
Know How SPA
Date of Agreement	Jul. 21, 2010
Payment to Acquire Intangible Assets	$ 3,000,000
KJR 10 Corp
Payment to Acquire Intangible Assets	$ 10,000		$ 7,500

LOANS PAYABLE - RELATED PARTI26

LOANS PAYABLE - RELATED PARTIES (Details Narrative) - USD ($)	Jun. 30, 2015	Sep. 30, 2014
Loan payable	$ 10,000	$ 10,000
Loans payable - related parties	95,000	205,817
Investor
Loan payable	10,000	10,000
Loan payable, balance	10,000	10,000
Chief Executive Officer
Loans payable - related parties		$ 95,000
Interest rate		5.00%
Loan payable, balance	8,500	$ 95,000
Chief Financial Officer
Loans payable - related parties		$ 122,100
Interest rate		5.00%
Loan payable, balance	$ 0
Director
Loans payable - related parties		$ 38,221
Interest rate	5.00%
Loan payable, balance	$ 0
Related Party Other
Loans payable - related parties		$ 35,696
Interest rate		5.00%
Loan payable, balance	$ 0	$ 36,996

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Sep. 30, 2014
Note payable - insurance financing					$ 51,613
Amortization of debt discounts			$ 7,675	$ 148,667
Insurance Financing #2
Date of Agreement			Sep. 30, 2014
Note payable - insurance financing	$ 51,613		$ 51,613
Note payable - insurance financing, down payment	10,322		10,322
Debt Instrument, Principal	$ 0		$ 0		51,613
Interest rate	6.45%		6.45%
Promissory Note 2
Date of Note			Dec. 21, 2011
Convertible Notes Payable	$ 150,000		$ 150,000
Convertible Notes Payable, amount to be repaid	$ 175,000		$ 175,000
Interest rate	31.23%		31.23%
Additional interest rate if late	10.00%		10.00%
Maturity Date			Jun. 21, 2012
Convertible Notes Payable, Balance	$ 175,000		$ 175,000		175,000
Promissory Note 29
Date of Note			May 31, 2013
Convertible Notes Payable	$ 25,000		$ 25,000
Interest rate	8.00%		8.00%
Conversion price per share	$ 0.05		$ 0.05
Convertible Notes Payable, Balance	$ 0		$ 0		25,000
Promissory Note 35 to 36
Date of Note			Aug. 31, 2013
Convertible Notes Payable	$ 250,000		$ 250,000
Convertible Notes Payable, Repayment			$ 25,000
Interest rate	8.00%		8.00%
Conversion price per share	$ 0.03		$ 0.03
Convertible Notes Payable, Balance	$ 225,000		$ 225,000		250,000
Promissory Note To Lender
Date of Agreement			Oct. 31, 2012
Convertible Notes Payable	$ 175,000		$ 175,000
Interest rate	10.59%		10.59%
Shares issued pursuant to Convertible Notes Payable	7,920,291		7,920,291
Convertible Notes Payable, Balance	$ 9,592		$ 9,592
Line Of Credit Current Borrowing Capacity	225,000		225,000
Accreted Interest			1,499
Amortization of debt discounts	0	$ 23,017	7,675	57,766
Loss (Gain) on the change in fair value of the conversion option	0	248,240	5,163	75,174
Fair value of the conversion option	0		0		5,164
Debt Discount, Amortized	0		$ 0		7,675
Debt Instrument Description			Material terms of the note include the following: 1. The Lender may make additional loans in such amounts and at such dates at its sole discretion. 2. The maturity date of each loan is one year after such loan is received. 3. The original interest discount is prorated to each loan received. 4. Principal and accrued interest is convertible into shares of the Company’s common stock at the lesser of $0.069 or 65%-70% (as defined) of the lowest trading price in the 25 trading days previous to the conversion. 5. Unless otherwise agreed to in writing by both parties, at no time can the Lender convert any amount of the principal and/or accrued interest owed into common stock that would result in the Lender owning more than 4.99% of the common stock outstanding. 6. There is a one-time interest payment of 10% of amounts borrowed that is due at the maturity date of each loan. 7. At all times during which the note is convertible, the Company shall reserve from its authorized and unissued common stock to provide for the issuance of common stock under the full conversion of the promissory note. The Company will at all times reserve at least 13,000,000 shares of its common stock for conversion. 8. The Company agreed to include on its next registration statement it files, all shares issuable upon conversion of balances due under the promissory note. Failure to do so would result in liquidating damages of 25% of the outstanding principal balance of the promissory note but not less than $25,000.
Convertible Note To Vendor
Date of Note			May 31, 2013
Convertible Notes Payable	$ 293,700		$ 293,700
Interest rate	12.00%		12.00%
Maturity Date			Aug. 31, 2014
Conversion price per share	$ 0.04		$ 0.04
Convertible Notes Payable, Balance	$ 0		$ 0		295,617
Warrants to purchase issued	50,000		50,000
Warrants to purchase issued, term			P5Y
Amortization of debt discounts				64,104
Loss (Gain) on the change in fair value of the conversion option	$ 0	$ (122,889)	$ (533,393)	$ 28,661
Fair value of the conversion option	$ 0		$ 0		$ 0

INCOME TAXES - Deferred Tax Ass

INCOME TAXES - Deferred Tax Assets (Details) - USD ($)	Jun. 30, 2015	Sep. 30, 2014
Deferred tax asset attributable to:
Net operating loss carryover	$ 1,412,233	$ 2,850,535
Intangible assets		1,200,000
Stock based compensation	$ 355,265	355,265
Accrued expenses	446,781	539,912
Total deferred tax assets	2,214,279	4,945,712
Valuation allowance	$ (2,214,279)	(2,116,712)
Net deferred tax asset		$ 2,829,000

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - Jun. 30, 2015 - USD ($)	Total
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Operating Loss Carryforwards	$ 2,829,000
Carryforward Expiration Date	Jan. 1, 2033
Provision for income tax benefits	$ 0

STOCKHOLDERS DEFICIENCY (Detail

STOCKHOLDERS DEFICIENCY (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Sep. 30, 2014
Series A Preferred Stock, Shares Authorized	5,500,000		5,500,000		5,500,000
Dividends payable	$ 304,197		$ 304,197		$ 251,242
Common stock, Issued	157,911,410		157,911,410		139,598,152
Common stock, Value	$ 157,914		$ 157,914		$ 139,601
Common Stock, Par Value	$ 0.001		$ 0.001		$ 0.001
Series A Preferred Stock, Issued and outstanding	885,000		885,000		885,000
Common Stock, Shares Authorized	200,000,000		200,000,000		200,000,000
Stock based compensation - general and administrative			$ 32,365	$ 27,556
Series A
Series A Preferred Stock, Shares Authorized	5,500,000		5,500,000
Dividends	$ 17,652	$ 17,652	$ 52,955	$ 52,955
Dividends payable	$ 304,197		$ 304,197		$ 251,242
Series A Preferred Stock, Issued and outstanding	885,000		885,000		885,000
Series B
Series B Preferred Stock, Shares Authorized	4,000,000		4,000,000		4,000,000
Series B Preferred Stock, Outstanding	0		0		0
Note Conversion
Date of Issuance			Oct. 31, 2014
Common stock, Issued	7,920,291		7,920,291
Additional Paid in Capital	$ 3,171		$ 3,171
Credit to Common Stock	$ 7,920		$ 7,920
Note Conversion #2
Date of Issuance			Mar. 31, 2015
Common stock, Issued	9,486,430		9,486,430
Additional Paid in Capital	$ 9,512		$ 9,512
Credit to Common Stock	$ 348,586		$ 348,586
Note Conversion #3
Date of Issuance			Jun. 30, 2015
Common stock, Issued	880,664		880,664
Additional Paid in Capital	$ 881		$ 881
Credit to Common Stock	$ 43,061		$ 43,061
4 Board Members
Date of Issuance			Jan. 6, 2011
Common stock, Issued	885,672		885,672
Common stock, Value	$ 27,556		$ 27,556
Common Stock, Par Value	$ 0.62		$ 0.62
Stock Option Agmt
Date of Issuance			Jan. 15, 2015
Common Stock Option, Issued	10,000,000		10,000,000
Common Stock Option, Exercise Price	$ 0.02		$ 0.02

Uncategorized Items - rgin-2015

Label	Element	Value
Net income (loss)	us-gaap_NetIncomeLoss	$ (308,864)
Net income (loss)	us-gaap_NetIncomeLoss	$ (456,909)